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Edited by Varda RotterAbstract Studies from murine embryogenesis and cancer cells
derived from human melanomas have identiﬁed a critical role
for the transcription factor PAX3 in the suppression of p53 pro-
tein accumulation and p53-dependent apoptosis. Here we show,
using a well-deﬁned over-expression system, that PAX3 sup-
presses p53-dependent transcription from promoters of p53-
responsive genes, notably BAX and HDM2-P2, and reduces
p53 protein abundance by promoting its degradation. We deﬁne
the functional domains of PAX3 required for this activity, and
furthermore present evidence that PAX3-dependent inhibition
of p53 is independent of binding of the N-terminal domain of
p53 to HDM2, the primary negative regulator of cellular p53
activity.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The p53 tumour suppressor is a nodal point for the response
to a range of cellular stresses [1]. It suppresses cellular replica-
tion and survival primarily by promoting the transcription of
speciﬁc target genes, including WAF1, which encodes the
cyclin-dependent kinase inhibitor p21WAF1, and BH3 family
pro-apoptotic genes BAX, PUMA and NOXA [1]. p53 also
activates the transcription of the gene encoding its negative
regulatory partner, HDM2 (Mdm2 in mice) [1,2], ensuring
p53 activity is maintained at low levels in proliferating cells.
The importance of correct control of p53 is clearly demon-
strated by the p53-dependent embryonic lethality observed in
Mdm2/ mice [3,4] and the ability of pharmacological
HDM2 antagonists to inhibit the proliferation of wild-type
p53-expressing cancer cells [5].
Pax proteins are a family of developmentally regulated tran-
scription factors with roles in proliferation, diﬀerentiation and
survival [6]. Mouse embryos homozygous for an inactivating
mutation in Pax3 (Splotch mice) die in mid-gestation with a*Corresponding author. Present address: Somers Cancer Research
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doi:10.1016/j.febslet.2007.11.056variety of neural tube defects and cardiac abnormalities [7].
The neuroepithelial tissue of these embryos exhibit a post-tran-
scriptional increase in p53 protein abundance, and p53-depen-
dent apoptosis with associated neural tube defects [8]. Pax3 is
down-regulated in later development and its expression in the
adult is restricted to a small number of highly specialised stem
cells such as melanocytes in the bulge region of hair follicles
[9]. PAX3 is, however, frequently expressed in human cancers
derived from cells of neural crest origin, notably neuroblastoma
and melanoma [6], and inhibition of PAX3 expression in mela-
noma cells results in p53 protein induction and apoptosis [10].
These ﬁndings indicate that a primary role ofPAX3 in the devel-
oping neural crest and potentially also certain human tumours,
involves the suppression of p53-dependent apoptotic pathways.
In contrast to HDM2, which is well documented as both
inhibiting the interaction of p53 with transcriptional co-activa-
tors, and targeting p53 for ubiquitination, nuclear export and
degradation [1]; the mechanism whereby PAX3 regulates p53
function is unknown. Here, we describe the results of a series
of experiments to dissect the molecular basis for the functional
interaction between these two proteins.2. Materials and methods
2.1. Cell culture, plasmids, transfections, mRNA and reporter gene
assays
H1299 and NIH3T3 cells were grown in RPMI 1640 (Invitrogen),
and DMEM (Invitrogen) respectively, supplemented with 10% foetal
bovine serum (Autogen Bioclear). The Hdm2luc03 and Hdm2luc13
luciferase reporter vectors contain 165 b.p. (132 to +33) and 616
b.p. (583 to +33) of the HDM2-P2 promoter region, respectively
[11]. Hdm2luc17 is a derivative of Hdm2luc13 with two independent
2 b.p. substitutions in its two p53-response elements. Baxluc contains
a 369 b.p. fragment of the BAX promoter in pGL3Basic [12]. Expres-
sion vectors for p53 (pC53SN3), and HDM2 (pCMVmdm2) as well as
the WAF1 promoter reporter (p21luc) were kind gifts from Profes-
sor Bert Vogelstein. pCDNA3p53F19A has been described [13].
pJ7PAX3 contains the entire human PAX3 coding sequence (splice
form PAX3c [14]) in pJ7x. Site-directed mutagenesis of pJ7PAX3 used
the following primers (forward primers only are shown): Stop281
(5 0-CTGGAGCCAATTAACTGATGGCTTTCAACC-3 0), SD42 (5 0-
CGAGTCAACCAGCTCCGAGGAGTATTTATC-3 0), WS265
(5 0-GAGGCCCGAGTGCAGTTCTGGTTTAGCAAC-3 0), N47H
(5 0-GGAGGAGTATTTATCCACGGCAGGCCTCTGCC-3 0). All
cell transfections used Lipofectamine 2000 reagent (Invitrogen) and to-
tal amounts of transfected plasmid were equalised using empty expres-
sion vector. Reporter assays were performed 48 h after transfection of
cells in 96 well plates using a Dual-Glo luciferase assay (Promega),
with normalisation to Renilla luciferase expressed from co-transfected
pRLSV40 (Promega) to produce relative luciferase units (RLU). Data
is expressed as ±S.E.M., or S.D. where n = 2. One-way ANOVA andblished by Elsevier B.V. All rights reserved.
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tistical analysis of the eﬀect of PAX3 in reporter assays. Asterisks
indicate signiﬁcance of the diﬀerence from the relevant no PAX3 con-
trol; *P < 0.05, **P 6 0.001. Reverse transcriptase(RT)-quantitative
(q)PCR was performed as described previously [15].
2.2. Protein analysis
Cells were washed with phosphate-buﬀered saline, pelleted by centri-
fugation at 1000 · g, snap frozen and stored at 80 C. Pellets were
lysed for 15 min at 4 C in denaturing urea buﬀer (7 M urea, 0.1 M
dithiothreitol, 0.05% Triton X-100, 25 mM NaCl, 20 mM HEPES pH
7.6) then clariﬁed by centrifugation at 13000 · g for 10 min at 4 C.
Protein concentrations were determined by the method of Bradford
(Bio-Rad). Immunoblotting was performed by standard procedures
and membranes were probed for PAX3 (Rabbit polyclonal, Active Mo-
tif), p53 (pAb421 or DO-1, Serotec) or EGFP (ab290, Abcam). DO-1
was used to detect p53 protein unless indicated otherwise. Bands were
visualised by chemiluminescence (Supersignal, Pierce) using a Fluor-S
MAX system (Bio-Rad), and quantiﬁed using Quantity One software
(Bio-Rad). Quantiﬁcation of the blots is expressed relative to EGFP.3. Results
3.1. PAX3 inhibits p53-induced transcription
Using a transient over-expression system in which the levels
and activities of the two proteins could be readily manipulatedFig. 1. Eﬀects of PAX3 on p53-dependent transcription. NIH3T3 (A) H1299
pRLSV40 and the indicated amount of p53 and PAX3 vectors, and lucif
experiments were conducted in H1299 cells using Hdm2luc03 (n = 8), Hdm
respectively. In (D) pGL3Basic was used instead of a reporter vector and RN
HDM2-P2 mRNA transcripts was determined by RT-qPCR. Data is normali
representative of two independent experiments (Transfections were in 60 mm
equivalents by surface area of a 96 well plate transfection.).and analysed, we ﬁrst investigated the eﬀect of PAX3 on p53-
dependent transcription from the promoter of the BAX gene
in cells which express low (NIH3T3, Fig. 1A) or no (H1299,
Fig. 1B) endogenous p53 protein. In both cell lines, p53 caused
a dose-dependent activation of the BAX promoter. This activa-
tion, but not basal promoter activity, was signiﬁcantly inhibited
by PAX3 (P < 0.001 in NIH3T3, at 2.5 ng p53 plasmid plus
100 ng PAX3 plasmid andP < 0.001 in H1299, at 5 ng p53 plas-
mid plus 100 ng PAX3 plasmid). We then extended this analysis
to the HDM2 promoter, which is activated by much lower lev-
els of p53 than the BAX promoter, and is therefore a better
model promoter, as it reduces the possibility of p53-induced cell
death inﬂuencing the experimental results. PAX3 caused signif-
icant inhibition of p53-dependent HDM2 promoter activity in
H1299 reporter assays (Fig. 1C) (P < 0.001 at 0.0625 ng p53
plasmid plus 100 ng PAX3 plasmid). Importantly, PAX3 also
suppressed p53-dependent expression of the endogenous
HDM2-P2 transcript (Fig. 1D). Fig. 1E conﬁrms that repres-
sion of HDM2 promoter activity by PAX3 is dependent upon
the presence of functional p53-response elements in the pro-
moter (compare Hdm2luc13, with Hdm2luc17, in which the
p53-response elements are mutated). Finally, we examined the
ability of PAX3 to repress p53-dependent transcription fromcells (B) were transfected with 100 ng of Baxluc or pGL3Basic, 20 ng
erase reporter assays performed (n = 4). In (C), (E) and (F) similar
2luc13 and 17 (n = 2) and p21luc (WAF1 promoter) (n = 4) reporters
A was extracted 48 h post transfection. The abundance of endogenous
sed to GAPDH, and is means ± S.D. for duplicate qPCR assays, and is
dishes. For ease of comparison, the amounts of plasmids shown are the
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HDM2-P2 and BAX promoters, PAX3 over-expression caused
a modest, but reproducible, up-regulation of WAF1 reporter
activity in both the absence and presence of transfected p53.
This may indicate that the ability of PAX3 to regulate p53-
dependent transcription of target genes can be promoter-
dependent.
3.2. Suppression of p53 function by PAX3 involves regulation of
p53 protein abundance, but is independent of p53 binding to
HDM2
The activity of p53 as a transcription factor can be regulated
at multiple levels including sequence-speciﬁc DNA-binding,
interaction with co-activators, sub-cellular localisation and
overall protein levels. In Fig. 2A, we show that co-expression
of PAX3 with p53 in the H1299 cell line causes a striking
reduction in p53 protein levels, for example to 17% and 26%
of no PAX3 controls in 0.6 ng and 1.2 ng p53-expression-vec-
tor lanes, respectively. Fig. 2B demonstrates that PAX3 over-
expression increases the rate of turnover of p53 protein in
H1299 cells. These ﬁndings are consistent with the increase
in p53 protein levels in PAX3 compromised melanoma cells
[10], and murine embryos [8], though the magnitude of the
eﬀect was greater, presumably as a consequence of the over-
expression system used.
We next investigated the requirement for HDM2 in PAX3-
mediated repression of p53 abundance and function. The
phenylalanine residue at position 19 of the amino terminus
of p53 is critical for the primary interaction between p53 and
the N-terminus of HDM2. This interaction causes a conforma-
tional shift in HDM2 that promotes a secondary interaction
between the two molecules that is required for p53 ubiquitina-
tion. Consequently, the F19A mutant of p53 is not targeted for
degradation by HDM2 in vivo unless a p53 N-terminus mimicFig. 2. Eﬀect of PAX3 on p53 protein abundance in H1299 cells. (A) Cells w
p53 plasmid and 1.8 lg of pJ7PAX3 (+) or pJ7 empty vector () and analy
1.125 ng p53 plasmid, 1.8 lg pGL3 Basic, 5 ng EGFPN1 and 0.9 lg pJ7PA
cycloheximide (CHX) was added and cells harvested for analysis at the times
for the p53 blot the + PAX3 lanes are a longer exposure than the No PAX3 la
assays, cells were transfected with 100 ng of Hdm2luc03 or pGL3Basic as i
PAX3 expression plasmids. (n = 4). p53F19A protein was detected by Wes
pAb421.is present to activate HDM2 in trans [13,16,17]. Firstly, we
established that it was necessary to transfect 0.5 ng of the
p53F19A expression plasmid to induce a comparable level of
p53-dependent transcription of Hdm2luc03 reporter plasmid
as obtained in Fig. 1 using the wild-type p53 expression vector
(not shown). Fig. 2C shows (inset) that levels of the p53F19A
protein are decreased by PAX3 over-expression. PAX3 also
caused a 6-fold reduction in the activation of a p53-dependent
reporter construct by 0.5 ng of p53F19A (Fig. 2C). Therefore,
neither the reduction of p53 protein level, nor the inhibition of
p53-dependent transcription by PAX3, requires binding of p53
through its N-terminal domain to its primary cellular inhibi-
tor, HDM2.
3.3. PAX3 must retain full integrity as a transcription factor to
inhibit p53 function
PAX3 translated from the best characterised PAX3c mRNA
splice form is a 479 amino acid protein. It has a modular struc-
ture with two distinct sequence-speciﬁc DNA-binding domains
(paired domain and homeodomain), an N-terminal transcrip-
tion inhibitory domain and a C-terminal transcription activa-
tion domain (Fig. 3A) [14,18]. To investigate the structural
elements of PAX3 required for inhibition of p53 function,
we created a series of mutant PAX3 expression constructs.
The truncation mutant Stop 281 was designed to lack the
transactivation domain, SD42 corresponds to an inactivating
point mutation in the paired domain found in the mouse mu-
tant Splotch-delayed [19]. This mutant aﬀects PAX3 transcrip-
tional activity but has a less severe phenotype than the Splotch
mutant used by Pani et al. [8]. WS265 encodes PAX3 with an
inactivating point mutation in the homeodomain that is asso-
ciated with Waardenburg syndrome in humans [20,21]. Expres-
sion of each of the mutant proteins was conﬁrmed in H1299
cells (Fig. 3B). All these mutations also markedly, thoughere transfected in 60 mm dishes with 5 ng EGFPN1, 1.8 lg pGL3Basic,
sed 48 h later. (B) H1299 cells were transfected in 60 mm dishes with
X3 or empty vector as indicated. At 48 h post transfection, 100 lg/ml
indicated. Representative of three independent experiments. Note that
nes to facilitate comparison of p53 turnover. (C) For luciferase reporter
ndicated, 20 ng pRLSV40 and the indicated amount of p53F19A and
tern blotting of lysates from scaled up transfections, using antibody
Fig. 3. Dissection of the PAX3 functional domains required to inhibit p53-dependent transcription. (A) PAX3 protein structure, and a description of
the mutants used in the study. ID = inhibitory domain, PD = paired domain, OM = octapeptide motif, HD = homeodomain, TA = transactivation
domain. (B) H1299 cells were transfected in 60 mm dishes with 5 ng EGFPN1, 1.8 lg pGL3Basic, 0.5 ng p53 plasmid and 0.9 lg of pJ7 empty vector
or the appropriate PAX3 mutant plasmid as indicated. Transfected cells were analysed by Western blotting 48 h later. (C and D) PAX3 mutants were
tested for repression of p53-dependent transcription in a reporter assay in H1299 cells in a 96 well format. Cells were transfected with 20 ng
pRLSV40, 100 ng pJ7 empty vector or the indicated PAX3 mutant and 100 ng reporter vector ((C) Hdm2luc03) or ((D) Baxluc). Open bars = 0 ng
p53 plasmid, closed bars = 0.0625 ng p53 plasmid (C) or 2.5 ng p53 plasmid (D). (n = 8). (E) The PAX3 mutant N47H was generated, and expression
conﬁrmed as in (A). (F) N47H was tested for repression of p53-dependent HDM2 promoter activity as in (C) (n = 2).
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tein abundance (Fig. 3B). The mutants were then tested for
repression of p53-dependent activity of the BAX (Fig. 3C)
and HDM2 (Fig. 3D) promoters. Whilst, as before, wild-type
PAX3 repressed p53-dependent transcription from both
promoters (P < 0.001 BAX, P < 0.001 HDM2), none of the
mutant PAX3 proteins had this eﬀect.
Biochemical and mutagenesis studies have shown that the
two DNA-binding domains of PAX3 are functionally interde-
pendent [21,22]. Indeed, the SD42 mutation results in loss of
DNA-binding by both paired- and homeo-domains [22]. We
therefore generated a further PAX3 mutant N47H (Fig. 3E),
that has been shown to abrogate DNA-binding by the paired
domain but increase homeodomain DNA-binding activity
[21]. N47H expressed in H1299 cells (Fig. 3E) was unable to
repress p53-dependent transcription (Fig. 3F). Therefore, the
ability of PAX3 to repress p53-dependent transcription is
dependent upon the ability of both its paired- and homeo-do-
mains to bind DNA (shown by N47H and WS265 mutants,
respectively), as well as the presence of an intact transcrip-
tional activation domain, as demonstrated by the Stop 281
mutant.4. Discussion
Both Pani et al. [8] and He et al. [10] demonstrated that loss
of PAX3 expression can result in a post-transcriptional in-crease in p53 protein abundance, as well as apoptosis which,
in the case of the developing neural tube, is p53 dependent
[8]. Here we have shown that this eﬀect of PAX3 on p53 pro-
tein abundance, and more speciﬁcally its rate of degradation,
can be recapitulated in the H1299 over-expression system, con-
ﬁrming the existence of a functional interaction between these
two proteins. The most widely recognised mechanisms for the
regulation of p53 protein degradation involves an interaction
between p53 and its ubiquitin E3-ligase HDM2, which results
in the ubiquitination and proteosome-mediated degradation of
p53 [1,23]. It was of interest, therefore, to discover that a well-
characterised, HDM2-binding defective mutant of p53, F19A,
was still down-regulated by PAX3. Therefore, whilst a role of
HDM2 that is independent of its binding to its primary inter-
action site on p53 has not been formally excluded, these data
suggests the involvement of an alternative p53 ubiquitin E3-
ligase such as COP1, [24] or an ubiquitin-proteosome indepen-
dent pathway.
P53 protein stability and its activity as a transcription factor
may be independently regulated [1], and previous reports have
not investigated the eﬀects of PAX3 loss on the transcriptional
targets of p53. Here we have shown that PAX3 does indeed in-
hibit the p53-dependent transcription from at least two p53-
dependent genes, including that encoding the pro-apoptotic
BAX protein. Intriguingly, the eﬀects of PAX3 exhibited a de-
gree of speciﬁcity to diﬀerent p53-responsive promoters; specif-
ically whilst HDM2-P2 and BAX promoters were suppressed,
theWAF1 promoter was not. Further work will be required to
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depenent apoptosis, compared to cell-cycle arrest, by PAX3.
We have also clearly demonstrated that mutations in either
of the two sequence-speciﬁc DNA-binding domains in
PAX3, or deletion of its C-terminal transactivation domain,
abrogate its ability to inhibit p53 activity. These PAX3 mu-
tants do retain a partial ability to reduce p53 protein abun-
dance, suggesting that, as is the case for HDM2, the eﬀect of
PAX3 on cellular p53 activity may not be solely through the
regulation of p53 abundance. Our analysis of the eﬀects of
PAX3 mutations on p53 function are consistent with a recent
analysis of the eﬀects of over-expressing PAX3 splice forms on
the response of melanocytes to genotoxic chemotherapy, in
that PAX3c and PAX3d, which are expressed in melanomas,
provided protection from etoposide-induced apoptosis,
whereas PAX3a and PAX3b, which produce truncated pro-
teins lacking the transactivation and homeodomains, did not
[25]. Our interpretation of these data is either that PAX3 is a
transcriptional activator of a gene, or genes, that regulate
p53 function, and that only PAX3 proteins with functional
paired- and homeo-DNA-binding domains are capable of acti-
vating the transcription of these genes, or that PAX3 and p53
proteins interact directly, but only fully functional PAX3 is
able to inﬂuence p53 activity. Future work will be required
to distinguish between these two possibilities, and fully deter-
mine the molecular basis for the functional interaction between
these two key proteins.
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